ArticleOpen forum infectious diseases2019
Prognostic Utility of the New Definition of Difficult-to-Treat Resistance Among Patients With Gram-Negative Bloodstream Infections.
Article in Open forum infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Pooled it
- Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis.PloS one · 2024Pooled it
- In Vitro Activity of Imipenem-Funobactam Against Clinical Isolates of Gram-Negative Bacilli.Antibiotics (Basel, Switzerland) · 2026Article
- Article
- Difficult-to-treat resistance (DTR), treatment, and outcomes of carbapenem-resistant Enterobacterales infections in the setting of IMP-type carbapenemase predominance in Japan.Microbiology spectrum · 2026Article
- The Role of Combination Antibiotic Therapy in Combatting Drug-ResistantAntibiotics (Basel, Switzerland) · 2026Review
- Contribution of mutational resistance mechanisms and acquired β-lactamases to cefiderocol/xeruborbactam susceptibility inAntimicrobial agents and chemotherapy · 2025Article
- Incidence and risk factors of resistant Pseudomonas aeruginosa infections: a multicenter study in Lebanese tertiary hospitals.BMC infectious diseases · 2025Observational
- Using a difficult-to-treat resistance index to gauge imbalance between countries' antibiotic resistance prevalence and access to antibiotics: a scoping review and concept proposal.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2025Article
- Time-Sensitive Antibiotic Adjustments in Gram-Negative Bacteremia: A Survival Perspective.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Endemic High-Risk Clone ST277 Is Related to the Spread of SPM-1-ProducingMicroorganisms · 2023Article
- The Hidden Cost of COVID-19: Focus on Antimicrobial Resistance in Bloodstream Infections.Microorganisms · 2023Review
- Article
- Early appropriate diagnostics and treatment of MDR Gram-negative infections.JAC-antimicrobial resistance · 2022Review
- Bloodstream Infections Caused by Carbapenem-Resistant Pathogens in Intensive Care Units: Risk Factors Analysis and Proposal of a Prognostic Score.Pathogens (Basel, Switzerland) · 2022Article
- Durlobactam in the Treatment of Multidrug-ResistantJournal of clinical medicine · 2022Review
- IncreasedAntimicrobial agents and chemotherapy · 2022Article
- What Doesn't Kill Them Makes Them Stronger: The Impact of the Resistance Patterns of UrinaryAntibiotics (Basel, Switzerland) · 2022Article
- Prevalence of Antibiotic Resistance Over Time in a Third-Level University Hospital.Microbial drug resistance (Larchmont, N.Y.) · 2022Article
- High Activity of N-Acetylcysteine in Combination with Beta-Lactams against Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo compare the prognostic utility of the new definition of difficult-to-treat resistance (DTR) vs established definitions in a cohort of patients with Gram-negative bloodstream infections (GNBSIs).
methodsThis was a retrospective single-center study of adult patients with monomicrobial GNBSI, hospitalized from 2013 to 2016. DTR was defined as isolate demonstrating intermediate or resistant phenotype to all reported agents in the carbapenem, beta-lactam, and fluoroquinolone classes. Carbapenem resistance (CR) was defined according to 2015 Centers for Disease Control and Prevention criteria. Each isolate was further classified according to the Magiorakos et al. criteria as non-multidrug-resistant (non-MDR), MDR, extensively drug-resistant (XDR), or pan-drug-resistant (PDR). The primary outcome was all-cause 30-day mortality.
resultsOverall, 1576 patients were analyzed. Enterobacteriaceae accounted for 88.7% of BSIs, with
conclusionsDTR seems a promising tool to identify challenging GNBSIs, mainly those due to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.